At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Brentuximab Vedotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single-Arm, Open-label Study of Brentuximab Vedotin in Chinese Patients With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
In Brief
A Phase 2 clinical trial evaluating Brentuximab Vedotin for Hodgkin Disease and Lymphoma, Large-Cell, Anaplastic. Completed, enrolled 39 participants across 7 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+ Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHodgkin Disease, Lymphoma, Large-Cell, Anaplastic
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartNov 2016
Primary CompletionAug 2018
Study CompletionFeb 2020
TodayJul 2026
First PostedOct 19, 2016
Enrollment StartNov 7, 2016
Primary CompletionAug 2, 2018
Study CompletionFeb 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.7 years ago
Interventions
Brentuximab Vedotindrug
Brentuximab vedotin IV infusion